4//SEC Filing
KKR Genetic Disorder L.P. 4
Accession 0001140361-21-005267
CIK 0001743881other
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 5:36 PM ET
Size
18.0 KB
Accession
0001140361-21-005267
Insider Transaction Report
Form 4
KKR Group Holdings Corp.
10% Owner
Transactions
- Sale
Common Stock
2021-02-17$60.47/sh−3,450,000$208,617,360→ 31,060,971 total(indirect: See footnotes)
KRAVIS HENRY R
10% Owner
Transactions
- Sale
Common Stock
2021-02-17$60.47/sh−3,450,000$208,617,360→ 31,060,971 total(indirect: See footnotes)
ROBERTS GEORGE R
10% Owner
Transactions
- Sale
Common Stock
2021-02-17$60.47/sh−3,450,000$208,617,360→ 31,060,971 total(indirect: See footnotes)
KKR Genetic Disorder L.P.
10% Owner
Transactions
- Sale
Common Stock
2021-02-17$60.47/sh−3,450,000$208,617,360→ 31,060,971 total(indirect: See footnotes)
KKR Fund Holdings L.P.
10% Owner
Transactions
- Sale
Common Stock
2021-02-17$60.47/sh−3,450,000$208,617,360→ 31,060,971 total(indirect: See footnotes)
KKR & Co. L.P.
10% Owner
Transactions
- Sale
Common Stock
2021-02-17$60.47/sh−3,450,000$208,617,360→ 31,060,971 total(indirect: See footnotes)
KKR Management LLC
10% Owner
Transactions
- Sale
Common Stock
2021-02-17$60.47/sh−3,450,000$208,617,360→ 31,060,971 total(indirect: See footnotes)
KKR Genetic Disorder GP LLC
10% Owner
Transactions
- Sale
Common Stock
2021-02-17$60.47/sh−3,450,000$208,617,360→ 31,060,971 total(indirect: See footnotes)
Footnotes (3)
- [F1]This amount represents the $62.50 secondary public offering price per share of common stock of BridgeBio Pharma, Inc. ("Common Stock") less the underwriting discount of $2.03125 per share for shares sold pursuant to an underwritten public offering
- [F2]The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Group Partnership L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLP, as the Series I preferred stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.
- [F3]Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001780408
Filing Metadata
- Form type
- 4
- Filed
- Feb 16, 7:00 PM ET
- Accepted
- Feb 17, 5:36 PM ET
- Size
- 18.0 KB